急性心肌梗死中宽松与限制性输血策略:随机对照试验的系统评价及频率学派与贝叶斯Meta分析
该系统评价纳入4项随机对照试验共4324例急性心肌梗死患者,比较宽松与限制性输血策略对90天内死亡率的影响。固定效应模型RR 1.16(95%CI 0.95-1.40)、随机效应模型RR 1.13(95%CI 0.67-1.91),均未显示死亡率显著降低(GRADE:低证据质量)。死亡或再发心梗复合终点固定与随机效应模型RR均为1.18(95%CI 1.01-1.37),异质性可忽略(I²=0%,P=0.46),结果不利于限制性输血(GRADE:极低证据质量),但主要由单项研究驱动。心源性死亡固定效应模型RR 1.42(95%CI 1.07-1.88),随机效应模型RR 1.05(95%CI 0.36-3.80)无统计学意义。作者提示在危重患者中应谨慎解读这些发现。
要点
- 4项RCT共4324例AMI患者,宽松vs限制性输血90天内死亡率固定效应RR 1.16(95%CI 0.95-1.40)、随机效应RR 1.13(95%CI 0.67-1.91),均未达统计学显著(GRADE低证据质量)。
- 死亡或再发心梗复合终点固定与随机效应模型RR均为1.18(95%CI 1.01-1.37),异质性I²=0%、P=0.46,不利于限制性输血(GRADE极低证据质量),但主要由单项研究驱动。
- 心源性死亡固定效应模型RR 1.42(95%CI 1.07-1.88)有统计学意义,随机效应模型RR 1.05(95%CI 0.36-3.80)无统计学意义。
- 再发心梗、卒中、非计划血运重建等其他次要终点均无统计学显著结果。
- 排除两项高偏倚风险研究的敏感性分析及贝叶斯分析均与主分析一致;作者提示危重患者中应谨慎解读。
适用人群与场景
- 急性心肌梗死(AMI)急性期患者,纳入4项随机对照试验共4324例参与者。
- 作者结论提示这些发现用于危重患者时应谨慎解读。
研究设计与关键结果
- 研究类型:系统评价与Meta分析(频率学派固定/随机效应模型及贝叶斯分析),检索MEDLINE、EMBASE和COCHRANE library,纳入随机对照试验。
- 共纳入4项RCT、4324例参与者;主要终点为心肌梗死后90天内最新测得的死亡率。
- 主要终点:固定效应模型RR 1.16(95%CI 0.95-1.40),随机效应模型RR 1.13(95%CI 0.67-1.91),均未显示死亡率显著降低(GRADE:低证据质量)。
- 复合终点死亡或再发心梗:固定效应与随机效应模型RR均为1.18(95%CI 1.01-1.37),异质性I²=0%、P=0.46,结果不利于限制性输血(GRADE:极低证据质量),但主要由单项研究驱动。
- 心源性死亡:固定效应模型RR 1.42(95%CI 1.07-1.88)有统计学意义,随机效应模型RR 1.05(95%CI 0.36-3.80)无统计学意义。
- 再发心梗、卒中、非计划血运重建等其他次要终点分析均无统计学显著结果。
- 敏感性分析(仅纳入Rob2评估为低偏倚风险的研究,即排除两项高偏倚风险研究)及贝叶斯分析均与主分析一致。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与Meta分析。
- 主要终点GRADE证据质量:低;复合终点死亡或再发心梗GRADE证据质量:极低。
- 复合终点结果主要由单项研究驱动。
- 作者结论:这些发现用于危重患者时应谨慎解读。
对床旁实践的改变
- 作者认为,与限制性输血策略相比,宽松输血策略在AMI患者中未显示早期死亡率显著获益(低证据质量)。
- 作者认为,宽松输血可能降低死亡或再发心梗复合终点风险(极低证据质量),但该结果主要由单项研究驱动。
- 作者提示这些发现用于危重患者时应谨慎解读。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The transfusion strategy in the acute phase of myocardial infarction (AMI) remains a debated topic with non-standardized guidelines. This study aimed to evaluate the impact of liberal versus restrictive transfusion strategies on mortality during AMI.
METHODS: A systematic search was conducted across MEDLINE, EMBASE, and the COCHRANE library databases, focusing on randomized controlled trials (RCTs). The primary endpoint was the latest measured mortality within 90 days following myocardial infarction (MI). Secondary endpoints included recurrence of MI, cardiovascular mortality, stroke occurrence, unplanned revascularization, and a composite endpoint of death or recurrent MI. Mixed and random-effects models were employed to estimate relative risks. Sensitivity analyses were conducted using two approaches: one incorporating only studies assessed as low risk of bias according to the Rob2 tool, and another employing a Bayesian analysis.
RESULTS: Four RCTs including a total of 4324 participants were analyzed. Neither the fixed-effect nor random-effects models demonstrated a significant reduction in mortality, with risk ratios (RR) of 1.16 (95% CI 0.95-1.40) for the fixed-effect model and 1.13 (95% CI 0.67-1.91) for the random-effects model (GRADE: low certainty of evidence). Sensitivity analyses, including the exclusion of two high-risk-of-bias studies and a Bayesian analysis, were consistent with the primary analysis. For the composite outcome death or MI both fixed-effect and random-effects models showed a statistically significant RR of 1.18 (95% CI 1.01-1.37) with negligible heterogeneity (I2 = 0%, p = 0.46), indicating results unfavorable to restrictive transfusion (GRADE: very low certainty of evidence). However, this result was primarily driven by a single study. For cardiac mortality, the fixed-effects model indicated a significant RR of 1.42 (95% CI 1.07-1.88), whereas the random-effects model showed non-significant RR of 1.05 (95% CI 0.36-3.80). Analyses of other secondary endpoints did not show statistically significant results.
CONCLUSIONS: Our analysis did not demonstrate a significant benefit in early mortality with a liberal transfusion strategy compared to a restrictive strategy for AMI, low certainty of evidence. Liberal transfusion may reduce the risk of the composite outcome death or MI, with very low certainty of evidence. These findings should be interpreted with caution in critically ill patients.
参考来源
- Braïk R, Jebali S, Blot PL, et al. Liberal versus restrictive transfusion strategies in acute myocardial infarction: a systematic review and comparative frequentist and Bayesian meta-analysis of randomized controlled trials. Ann Intensive Care. 2024. PMID: 39340600. doi:10.1186/s13613-024-01376-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。